2019 International Congress of Diabetes and Metabolism

Skip Navigation: Skip to contents

REGISTER
Mypage
- Admin
- Home
- Login

Research group and committee session

RG1 NAFLD: today & tomorrow Dx & Tx of NAFLD; today & tomorrow	15:30~17:30 / Thursday 10 October Convention hall B Chairman:Won-Young Lee	Overview
Organizers: KDA research group on fatty liver disease This session titled, ‘diabetes together with NAFLD’ is a translational session that is designed to provide an opportunity for clinicians and basic researchers to understand potential diagnostic and therapeutic areas for NAFLD in patients with diabetes. In this session, a noninvasive tool for detecting NAFLD and a variety of therapeutic targets based on the novel NAFLD pathophysiologies especially in T2D patients, will be presented and discussed. Especially, influential heads of pharmaceutical companies will give an insight for ongoing and future NAFLD drugs. This session will be the first step toward better understanding of an importance of NAFLD in T2D.
Robert J Heine Eli Lilly and Company, USA	RG1-1Diabetes, cardiovascular disease and NAFLD: a global metabolic emergency requiring urgent measures
Dae Ho Lee Gachon University, Korea	RG1-2Noninvasive evaluation of NAFLD and its progression
Bo Kyung Koo Seoul National University, Korea	RG1-3Reposition of antidiabetic drug to NAFLD
Avelina Karin Conde-Knape Novo Nordisk, Denmark	RG1-4Metabolic mechanisms for the treatment of NASH

RG2 Vascular cell biology Heart failure as a diabetic complication	15:30~17:30 / Thursday 10 October Diamond hall Chairman:Joong Yeol Park	Overview
Organizers: KDA research group on diabetic vascular cell biology This session is organized by vascular cell research group of Korean Diabetes Association (KDA) in conjunction with Korean Society of Lipid and Atherosclerosis (KSoLA) to discuss about the relationship between diabetes and heart failure, which is a hot topic in the field of diabetes treatment due to recently observed favorable outcome of sodium-glucose cotransporter 2 (SGLT2) inhibitors on hospitalization for heart failure in patients with diabetes. Two speakers from Vasular Cell Research Group of KDA will talk about the clinical aspects of and the effects of SGLT2 inhibitors on heart failure in patients with diabetes. Two speakers from KSoLA will review the recent development in heart failure research.
Sang Eun Lee University of Ulsan, Korea	RG2-1The pathologic mechanism of heart failure in general
Seung-Pyo Lee Seoul National University, Korea	RG2-2Noninvasive imaging, how it can help evaluate heart failure
Jaetaek Kim Chung-Ang University, Korea	RG2-3New role of insulin and IGF-1 receptors in the heart
Eun-Jung Rhee Sungkyunkwan University, Korea	RG2-4Protective mechanism of SGLT2 inhibitors on heart failure

RG3 Metabolism, signaling, regulator Novel regulator of metabolic disturbances	09:00~10:40 / Friday 11 October Emerald hall A Chairman:In-Kyu Lee	Overview
Organizers: KDA research group on development of new drug and technology on metabolic disease This session titled, ‘Novel regulator of metabolic disturbances’ is a translational session that is designed to provide an opportunity for clinicians and basic researchers to understand novel pathogenesis and potential therapeutic targets for metabolic diseases. It will comprehensively deal with the role of estrogen-related receptor gamma as a therapeutic target of anaplastic thyroid cancer, serotonin signals to regulate hepatic steatosis and other new emerging novel drug targets and current industrial development for metabolic diseases. This session will enhance the understanding for the recent advancement for novel drugs of metabolic diseases.
Yong Hyun Jeon DGMIF, Korea	RG3-1Estrogen-related receptor gamma for novel therapeutic target of anaplastic thyroid cancer
Seung Jae Baek Hanmi Pharmaceuticals, Korea	RG3-2Evolution of incretin: from mono to triple
Hail Kim KAIST, Korea	RG3-3A new strategy to treat NAFLD by inhibiting peripheral serotonin
In-Kyu Lee Kyungpook National University, Korea	RG3-4AMPK: an important target for treatment of metabolic syndrome by improving mitochondrial function

RG4 Beta cell, transplantation Islet biology and surrogate beta-cells	13:30~15:00 / Saturday 12 October Emerald hall B Chairman:Kun Ho Yoon	Overview
Organizers: KDA research group on beta cell and islet transplantation This session titled, ‘Islet biology and surrogate beta-cells’ is a basic session that is designed to provide an opportunity for clinicians and basic researchers to understand the islet biology and novel approaches to surrogate beta-cells. In this session, mechanisms related to the beta cell function and survival will be presented first. Then potential approaches of intestinal cells as insulin-producing cells will be addressed. This session will provide a better understanding of the importance of beta-cells in pathophysiology and therapy in diabetes mellitus.
Dae-Kyu Song Keimyung University, Korea	RG4-1Beta cell glucose sensing-glucoreceptors and glucose metabolism
Ji-Won Kim The Catholic University of Korea, Korea	RG4-2Generating surrogate beta-cells from iPS cells and intestinal organoids
Jun Sung Moon Yeungnam University, Korea	RG4-3Insulin production from gut K-cells as surrogate beta-cells
Ki-Ho Song The Catholic University of Korea, Korea	RG4-4Comparison of enteroendocrine cells and pancreatic β-cells

RG5 New angles in DPN New angles in DPN	13:30~15:00 / Saturday 12 October Diamond hall Chairman:Tae Sun Park	Overview
Organizers: KDA research group on Diabetic Neuropathy This session titled, ‘New angles in DPN’ is a translational session that is designed to provide a place for clinicians and basic researchers to understand diagnostic tools, novel biomarkers and potential therapeutic areas for diabetic neuropathy in people with diabetes. It will comprehensively deal with manipulating mitochondrial function to treat diabetic neuropathy in preclinical and clinical studies, novel biomarkers for diabetic neuropathy focusing on oxidative stress and inflammation and tools for screening and diagnosis of diabetic neuropathy- from old to new. This session will provide a better understanding of diagnosis and managements of diabetic neuropathy.
Nigel A. Calcutt University of California, San Diego, USA	RG5-1Manipulating mitochondrial function to treat diabetic neuropathy: preclinical and clinical studies
Sang Soo Kim Pusan National University, Korea	RG5-2Novel biomarkers for diabetic neuropathy focusing on oxidative stress and inflammation
Tae-Kyeong Lee TBD	RG5-3Tools for screening and diagnosis of diabetic peripheral neuropathy- from old to new
Panel Discussion Seong Su Moon (Dongguk University, Korea) Jung Min Lee (The Catholic University of Korea, Korea) Seon Mee Kang (Daejeon Sun Hospital, Korea)

Should we add renal benefits of SGLT2 inhibitors in next Korean Diabetes Guidelines?
CS1 Diabetes guideline : Unmet needs in Korean Diabetes Guidelines 2019	13:20~15:20 / Friday 11 October Convention hall A Chairman:Yu-Bae Ahn, Hyuk-Sang Kwon	Overview
Organizers: Committee of clinical practice guideline This session titled, ‘Unmet needs in Korean Diabetes Guidelines 2019’ is a clinical session that is designed to provide an opportunity for clinicians to understand the potential therapeutic use for SGLT2 inhibitors in patients with a kidney disease. In this session, we can discuss whether renal benefits of SGLT2 inhibitors should be added to the diabetes guidelines. We will also announce a consensus statement of the Korean Diabetes Association and the Korean Society of Nephrology regarding the discontinuation of metformin before contrast procedures.
Hae Jin Kim Ajou University, Korea	CS1-1Are SGLT2 inhibitors effective in diabetic kidney disease?
Sungjin Chung The Catholic University of Korea, Korea	CS1-2Potential use of sodium-glucose cotransporter-2 inhibitors in non-diabetic kidney disease
Metformin discontinuation before contrast procedures: joint consensus statement of Korean Diabetes Association and Korean Nephrology Society
Kyu Yeon Hur Sungkyunkwan University, Korea	CS1-3The position of the Korean Diabetes Association
Dong Won Lee Pusan National University, Korea	CS1-4The position of the Korean Society of Nephrology
Hyuk-Sang Kwon The Catholic University of Korea, Korea	CS1-5Consensus statement on the recommendation of metformin discontinuation before contrast procedures

CS2 Diabetes and metabolism journal session Diabetes-DMJ joint symposium	13:20~14:20 / Friday 11 October Emerald hall A Chairman:Kyu Chang Won, Tae Seo Sohn	Overview
Sang Youl Rhee Kyung Hee University, Korea	CS2-1Air pollution has a significant negative impact on intentional efforts to lose weight: a global scale analysis
Kyoung Hwa Ha Ajou University, Korea	CS2-2Development and validation of the Korean diabetes risk score: a 10-year national cohort study
Jun Namkung Yonsei University, Korea	CS2-3Inhibition of serotonin synthesis induces negative hepatic lipid balance.
Kyeong Jin Kim Korea University, Korea	CS2-4Ten-year mortality trends for adults with and without diabetes mellitus in South Korea, 2003 to 2013
Seung-Hwan Lee The Catholic University of Korea, Korea	CS2-5Serum betatrophin concentrations and the risk of incident diabetes: a nested case-control study from Chungju Metabolic disease Cohort (CMC)

CS3 National diabetes management [Korean] Prospects for a country-based diabetes care model: based on the pilot project of the chronic disease management	09:00~11:00 / Saturday 12 October Flamingo Chairman:Tae Sun Park, Seok O Park
Hyeung Keun Park Agency of NCD Management in Primary Care, Korea	CS3-1Issues and challenges in pilot project of NCD management in primary care
Sin Gon Kim Korea University, Korea	CS3-2Nationwide diabetes care model - now is the time to pivot
Panel Discussion Dong-Hyeok Cho (Chonnam National University, Korea) Seak Ki Yun (Cheonan Endo Medical Clinic, Korea) Jeong Rim Lee (Asan Medical Center, Korea) Won Gyoung Kim (Seoul National University, Korea)